Michel Vounatsos, Biogen CEO (Photo by Dina Rudick/The Boston Globe via Getty Images)

Bleed­ing cash from its Alzheimer's fran­chise, Bio­gen preps 'deals of all sizes' as rev­enue shriv­els

Bio­gen put out its Q4 and 2021 re­sults to­day, and the num­bers paint a pic­ture of a deeply trou­bled big biotech with prof­its slid­ing fast …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.